 |
|
|
|
|
| Que sont les EUROCONFERENCES ? | |
| What are the EUROCONFERENCES ? | |
| EUROCONFERENCES passées | |
 |
|
Protein kinase inhibitors / Inhibiteurs des protéine-kinases
Extensive abstracts / Résumés étendus
Using structures to inform the optimization of protein kinase inhibitors
Martin E. M. Noble, University of Oxford, United Kingdom
Inhibitors of NEMO, a crucial protein regulating the IKK complex of the NF-kB pathway
Michel Véron, Institut Pasteur, Paris, France
Tyrosine kinase inhibitors in leukemia
James D. Griffin, Dana Farber Cancer Institute, Boston, USA
Structural and mechanistic properties of oncogenic protein kinases that manifest resistance: Chemical biology and drug design strategies
Tomi K. Sawyer, Ariad Pharmaceuticals, Inc., Cambridge, USA
Targeting Src family kinases for anticancer therapy
Francisco Cruzalegui, Institut de Recherches Servier, Croissy-sur-Seine, France
Targeting the subunits of Protein-kinase CK2 in cancer therapy
Claude Cochet, CEA, Grenoble, France
Pharmacological inhibitors of disease-relevant cyclin-dependent kinases
Laurent Meijer, Station Biologique de Roscoff, France
Modular interaction domains in protein kinase signaling
Tony Pawson, Samuel Lunenfeld Research Institute, Toronto, Canada
The effects of Cdk inhibitors in a mouse model for Alzheimer's disease
Li-Huei Tsai, Harvard Medical School, Boston, USA
Tyrosine kinases of the focal adhesion kinase family
Jean-Antoine Girault, Université Pierre et Marie Curie, Institut du Fer à Moulin, Paris, France
Activation and inhibition of the PDGF receptor family
Nick J. Dibb, Imperial College London, United Kingdom
MLK crystallography and the design of family selective MLK inhibitors for the treatment of neurodegenerative diseases
Robert L. Hudkins, Cephalon, Inc., West Chester, USA
Protein kinases and diseases in the postgenomic era
Tony Hunter, The Salk Institute, La Jolla, USA
Essential Ser/Thr protein kinases as potential targets for the development of novel antibiotics against mycobacterial diseases
Pedro Alzari, Institut Pasteur, Paris, France
Eukaryotic-like protein kinases as targets for the development of compounds to combat Mycobacterium tuberculosis
Jean Pieters, University of Basel, Switzerland
Divergent protein kinases: an Achille's heel of malaria parasites and other protozoa?
Christian Doerig, University of Glasgow, United Kingdom
Protein tyrosine kinases in bacteria
Christophe Grangeasse, Institut de Biologie et Chimie des Protéines, Lyon, France
PKA dynamics: novel strategies for inhibitors
Susan S. Taylor, University of California, San Diego, USA
A chemogenomic approach to kinase drug discovery
Kevin P. Williams, Amphora Discovery Corp., Durham, USA
Martin E. M. Noble, University of Oxford, United Kingdom
Inhibitors of NEMO, a crucial protein regulating the IKK complex of the NF-kB pathway
Michel Véron, Institut Pasteur, Paris, France
Tyrosine kinase inhibitors in leukemia
James D. Griffin, Dana Farber Cancer Institute, Boston, USA
Structural and mechanistic properties of oncogenic protein kinases that manifest resistance: Chemical biology and drug design strategies
Tomi K. Sawyer, Ariad Pharmaceuticals, Inc., Cambridge, USA
Targeting Src family kinases for anticancer therapy
Francisco Cruzalegui, Institut de Recherches Servier, Croissy-sur-Seine, France
Targeting the subunits of Protein-kinase CK2 in cancer therapy
Claude Cochet, CEA, Grenoble, France
Pharmacological inhibitors of disease-relevant cyclin-dependent kinases
Laurent Meijer, Station Biologique de Roscoff, France
Modular interaction domains in protein kinase signaling
Tony Pawson, Samuel Lunenfeld Research Institute, Toronto, Canada
The effects of Cdk inhibitors in a mouse model for Alzheimer's disease
Li-Huei Tsai, Harvard Medical School, Boston, USA
Tyrosine kinases of the focal adhesion kinase family
Jean-Antoine Girault, Université Pierre et Marie Curie, Institut du Fer à Moulin, Paris, France
Activation and inhibition of the PDGF receptor family
Nick J. Dibb, Imperial College London, United Kingdom
MLK crystallography and the design of family selective MLK inhibitors for the treatment of neurodegenerative diseases
Robert L. Hudkins, Cephalon, Inc., West Chester, USA
Protein kinases and diseases in the postgenomic era
Tony Hunter, The Salk Institute, La Jolla, USA
Essential Ser/Thr protein kinases as potential targets for the development of novel antibiotics against mycobacterial diseases
Pedro Alzari, Institut Pasteur, Paris, France
Eukaryotic-like protein kinases as targets for the development of compounds to combat Mycobacterium tuberculosis
Jean Pieters, University of Basel, Switzerland
Divergent protein kinases: an Achille's heel of malaria parasites and other protozoa?
Christian Doerig, University of Glasgow, United Kingdom
Protein tyrosine kinases in bacteria
Christophe Grangeasse, Institut de Biologie et Chimie des Protéines, Lyon, France
PKA dynamics: novel strategies for inhibitors
Susan S. Taylor, University of California, San Diego, USA
A chemogenomic approach to kinase drug discovery
Kevin P. Williams, Amphora Discovery Corp., Durham, USA
Patrick Zarrinkar, Ambit Biosciences, San Diego, USA
Chemical biology in targeted drug discovery - The next generation of kinase inhibitors
Bert Klebl, GPC Biotech, Martinsried, Germany
High throughput cellular screen and profiling technologies and their implication in target and drug discovery
Markus Warmuth, Genomics Institute of the Novartis Research Foundation, San Diego, USA
Protein kinase inhibitors by design
Pascal Furet, Novartis, Basel, Switzerland
Fragment based drug discovery for the rational design of kinase inhibitors
Harren Jhoti, Astex Therapeutics, Cambridge, United Kingdom
Chemical biology in targeted drug discovery - The next generation of kinase inhibitors
Bert Klebl, GPC Biotech, Martinsried, Germany
High throughput cellular screen and profiling technologies and their implication in target and drug discovery
Markus Warmuth, Genomics Institute of the Novartis Research Foundation, San Diego, USA
Protein kinase inhibitors by design
Pascal Furet, Novartis, Basel, Switzerland
Fragment based drug discovery for the rational design of kinase inhibitors
Harren Jhoti, Astex Therapeutics, Cambridge, United Kingdom